Clinical Trials Browser

Active not recruiting × INDUSTRY × Neoplasms, Plasma Cell × Clear all

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase 2 Active not recruiting

187 enrolled 14 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03162536 2025-09-08

ARQ 531-101

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04354246 2025-05-22

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Phase 1 Active not recruiting

GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell